Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice

International Journal of Dermatology

Volumn 47, Issue 7, 2008, Pages 737-742

  Vermaat, Hester ^a   Kirtschig, Gudula ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; RISEDRONIC ACID; STEROID; VITAMIN D;

AGING; ARTICLE; BODY MASS; BODY POSITION; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE NECROSIS; BONE TURNOVER; CALCIUM BALANCE; CLINICAL TRIAL; CORNEA INJURY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DERMATOLOGY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; EARLY INTERVENTION; ESOPHAGUS ULCER; EXERCISE; FAMILY HISTORY; FLUSHING; FOOD; FOOD DRUG INTERACTION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GENDER; HIP FRACTURE; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOCALCEMIA; IMMOBILIZATION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; MUSCULOSKELETAL DISEASE; NAUSEA; NUTRITIONAL VALUE; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATIENT COUNSELING; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; STOMACH EROSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UVEITIS; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

BONE DENSITY; CALCIUM; DERMATOLOGY; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; LONG-TERM CARE; MALE; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SKIN DISEASES; TREATMENT OUTCOME; VITAMIN D;

EID: 47649105374     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03679.x     Document Type: Article

References (48)

1. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.
2. Reid IR. Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 1997; 137: 209-217.
3. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. Q J Med 2000; 93: 105-111.
4. van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51: 601-607.
5. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporosis Int 2004; 15: 323-328.
6. De Laet CE, Van Hout BA, Pols HA. Osteoporosis in the Netherlands; A Burden of Illness Study. Rotterdam: Institute for Medical Technology Assessment, 1996.
7. Pols HPA, Wittenberg J, Asten van P, et al. Osteoporose Tweede Herziene Richtlijn 2002. URL http://www.cbo.nl.
8. Kanis JA, Stevenson M, McCloskey EV, et al. Glucocorticoid-induced osteoporosis: A systematic review and cost-utility analysis. Health Technol Assess 2007; 11: 1-231.
9. Buckley LM, Marquez M, Hudson JO, et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998; 25: 2195-2202.
10. Liu RH, Albrecht J, Werth VP. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006; 142: 37-41.
11. Williams LC, Nesbitt LT Jr. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2001; 19: 63-77.
12. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol 2001; 137: 477-481.
13. Lamb A, Werth V. Osteoporosis in health and disease: A dermatologist's perspective. Dermatol Clin 2006; 24: 241-249.
14. Yood RA. Prevention of glucocorticoid-induced osteoporosis: Why are we doing so poorly? J Rheumatol 2006; 33: 1461-1463.
15. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis, 2001 up-date. Arthritis Rheum 2001; 44: 1496-1503.
16. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005; 64: 176-178.
17. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An up-date. J Intern Med 1998; 244: 271-292.
18. Devogelaer JP, Goemare S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian Bone Club. Osteoporosis Int 2006; 17: 8-19.
19. Anonymous. Guidelines on the prevention and treatment of glucocorticoid induced osteoporosis by the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. URL http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/index.asp.
20. McIlwain HH. Glucocorticoid-induced osteoporosis: Pathogenesis, diagnosis, and management. Prev Med 2003; 36: 243-249.
21. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79: 129-137.
22. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
23. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporosis Int 2002; 13: 777-787.
24. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 2007; 26: 144-153.
25. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology 2000; 39: 1383-1389.
26. Roujeau JC. Pulse glucocorticoid therapy. The 'big shot' revisited. Arch Dermatol 1996; 132: 1499-1502.
27. Haugeberg G, Griffiths B, Sokoll KB, et al. Bone loss in patients treated with pulses of methylprednisolone is not negligible: A short term prospective observational study. Ann Rheum Dis 2004; 63: 940-944.
28. Sinigaglia L, Varenna M, Binelli L, et al. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. J Rheumatol 1999; 26: 1280-1284.
29. Nzeusseu Toukap A, Depresseux G, Devogelaer JP, et al. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 2005; 14: 517-520.
30. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773.
31. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 961-968.
32. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-1752.
33. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3.years follow up. J Rheumatol 1996; 23: 995-1000.
34. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; 2: CD000952.
35. Boonen S, Vanderschueren D, Haentjens P, et al. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med 2006; 259: 539-552.
36. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-2318.
37. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-1013.
38. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: A comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919-924.
39. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-285.
40. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-299.
41. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; 2: CD001347.
42. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278-2281.
43. Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. Cornea 2006; 25: 1133-1138.
44. Richards JC, Wiffen SJ. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea 2006; 25: 1100-1101.
45. Maalouf NM, Odvina CV, Kim PJ, et al. Bisphosphonate-induced hypocalcemia: Report of 3 cases and review of literature. Endocr Pract 2006; 12: 48-53.
46. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; 2: CD001983.
47. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-1633.
48. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703.